Radiopharm Theranostics (ASX:RAD) has hit a significant milestone in its Phase 2b clinical trial evaluating RAD101, announcing that the study has now reached 50 per cent of its planned patient enrollment. …
Radiopharm Theranostics reaches enrollment milestone in Phase 2b trial for RAD101
November 17, 2025 Australian Biotech
Latest Video
New Stories
-
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech -
OncoSil announces first UK patient treated with its pancreatic cancer treatment
December 10, 2025 - - Australian Biotech -
Health Department clarifies PBAC plan after confusion over paediatric access to biologics
December 10, 2025 - - Latest News -
If this was the plan, why wasn't it included in the response to questions last week?
December 10, 2025 - - Latest News -
Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy
December 9, 2025 - - Australian Biotech